JNJ-70218902 — Investigational Agent
T-Cell Engager · Phase 1 · Janssen (Johnson & Johnson)
Mechanism of Action
A bispecific antibody engaging CD3 on T cells and TMEFF2, a tumor-associated antigen overexpressed in prostate cancer, redirecting cytotoxic T cells to lyse TMEFF2-expressing tumor cells.
Investigational Indications
- Metastatic castration-resistant prostate cancer
- Advanced solid tumors